All worlds
TEN WORLDS · 06 · LONGEVITY

Longevity

This world combines the biggest promises with the thinnest human evidence in biohacking. We show the few levers with hard outcome data — and clearly name what is experimental and what is still pure animal speculation.

Reviewed

What this world covers

Longevity is the research field that turns insights about aging biology into actionable levers — with the goal of extending healthy lifespan (healthspan), ideally also absolute lifespan. This world covers the discussed pharmacological substances (NMN, NR, rapamycin, metformin, senolytics, AMPK activators), bioenergetic strategies (mitochondrial optimization, NAD+ pathway, spermidine/autophagy) and measurement tools (epigenetic clocks, biomarker panels).

An honest stocktake is important: no medication and no supplement combination is yet proven to extend lifespan in humans. What we have are lifestyle interventions with hard outcome data (Mediterranean diet, strength training, sleep, social bonds) and pharmacological substances with strong animal data whose human translation is still open. Communicating this difference transparently is part of the world — not a sheepish disclaimer.

Why the order matters

In no other world is the temptation greater to skip lifestyle basics and reach directly for speculative substances. Anyone paying 200 €/month for NMN, resveratrol and spermidine while sleeping 6 h, doing no strength training and eating 250 g of meat per day is optimizing in the wrong order.

The most robust longevity effects in humans come from lifestyle:

  • PREDIMED (n=7447): Mediterranean diet −30 % cardiovascular endpoints
  • Momma 2022 (n=480 000): strength training −10–20 % all-cause mortality
  • Laukkanen (n=2315): sauna 4–7×/week −50 % CV mortality, −66 % dementia
  • Adventist Health Study (n=96 000): combined lifestyle factors = 10 years of life expectancy

These levers are reproducible, measurable and inexpensive. Pharmacological longevity strategies are complement — not replacement.

The most important levers

Lifestyle foundation

The standard recommendations of geriatrics and gerontology are not sexy but outcome-strong:

  • Mediterranean diet: olive oil, fish 2×/week, vegetables, nuts, legumes
  • Strength training: 2–3×/week, heavy multi-joint lifts
  • Cardio: 150 min moderate or 75 min HIIT per week
  • Sleep: 7–9 h, consistent times
  • Sauna: 4–7×/week, 80–90 °C, 15–20 min
  • Social bonds: strong social networks are 50 % more predictive of mortality than smoking in meta-analyses

NAD+ pathway (NMN, NR)

NAD+ declines 40–50 % with age between 30 and 80. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that reproducibly raise NAD+ levels in humans.

Evidence status:

  • Animal studies (mouse, monkey): mitochondrial improvement, some aging markers push back
  • Human studies: NAD+ rises (+30–60 % at 250–500 mg/day, 8 weeks)
  • Outcome studies in humans: so far no hard endpoints (mortality, incidence)

Practical: favorable side-effect profile, acceptable bet, no proven effect on lifespan.

Rapamycin

Pharmacologically the most strongly validated substance for mammalian lifespan extension. mTOR inhibition partially mimics caloric restriction effects.

Animal data: mouse lifespan +9–14 % reproducibly Human data: approved for transplant patients and some oncology indications. Off-label use in longevity practitioners in pulsatile dose (5–10 mg/week, often with 2–4 weeks off). Trade-offs: delayed wound healing, lipid values rise, possible insulin resistance, mucositis.

Stance: not for self-medication from the internet. Anyone considering rapamycin needs a physician with longevity experience and monitoring (blood tests, mouth inspection, wound healing awareness).

Metformin

Diabetes standard medication for decades, excellent safety profile, possibly life-extending even without diabetes (observational data mixed, TAME results pending).

Mechanisms:

  • AMPK activation
  • Mitochondrial complex-I modulation
  • Reduced hepatic glucose production
  • Possibly direct effects on aging pathways

Current status: off-label use in healthy adults experimental, TAME Phase III pending. Pragmatically: not expensive, well-tolerated (except initial GI effects), but not yet sufficient for routine recommendation to healthy adults.

Senolytics

Substances that selectively eliminate senescent ("zombie") cells. Strong in animal trials, very early in humans.

Candidates:

  • Fisetin (in strawberries): best-tolerated, 20 mg/kg over 2–3 days monthly is a discussed protocol
  • Quercetin + dasatinib: stronger but dasatinib is an oncology medication with side effects
  • Spermidine (wheat germ, soybeans): autophagy induction, not a classical senolytic but overlapping effects

Practical status: animal hope > human evidence. Low risks with fisetin and spermidine, higher with dasatinib protocols.

How we rate evidence

In this world the most critical discipline is: not mixing animal and human evidence. We weight:

  1. Human RCTs with outcome endpoints (mortality, disease incidence) — currently not available for any longevity substance
  2. Human RCTs with biomarker endpoints (NAD+, epigenetic clocks, inflammation) — available for NMN, NR, some senolytics
  3. Mammalian lifespan studies (mouse, rat, monkey) — available for rapamycin, acarbose, 17α-estradiol
  4. Mechanism + cross-sectional data — hypothesis-generating

Important: epigenetic clocks and biomarkers are surrogates — not the goal itself. A NMN-induced reduction of DunedinPACE by 0.02 is not the same as proven life extension.

Most common effects and interactions

Longevity substances interact with the same pathways the body regulates via other levers:

  • NMN + resveratrol: theoretically synergistic (sirtuins), evidence for synergy in humans thin.
  • Rapamycin + insulin / glucose management: rapamycin worsens insulin sensitivity — caution in prediabetic patients.
  • Metformin + B12: metformin lowers B12 absorption — check status regularly, supplement if needed.
  • Fisetin + quercetin: similar pathways, acute combination possible, sustained high-dose not established.
  • Spermidine + autophagy inducers (fasting, resveratrol): overlapping mechanisms, additive effects plausible.

What does NOT belong in this world

  • Micronutrients for status correction → World 01 (Foundation)
  • Lifestyle interventions like strength training, sauna → World 02 (Methods) — even though they are the strongest longevity levers
  • GH secretagogues and hormone substitution → World 03/04
  • Classical adaptogens for stress → World 05 (Cognition)
  • Recovery protocols → World 10 (Recovery)

Omega-3 is longevity-relevant but belongs primarily in micronutrient basics. Creatine has weak longevity signals (especially for cognition in old age) but is performance-central.

How Biohacking AI operationalizes this

This is the world with the greatest discrepancy between marketing and evidence. Four tools help keep them apart:

  1. The Biological-age tracker imports epigenetic tests, blood tests and lifestyle data — and visualizes trajectory, not snapshots. Individual values are not informative.
  2. The Studies database separates strictly by human studies, mammalian studies and cell studies. Anyone with only mouse data gets no green light.
  3. The Forum collects stacks and blood test trajectories — moderated by advisors with gerontology background, without MLM schemes or affiliate posts.
  4. The Coach is more conservative here than elsewhere: off-label rapamycin/metformin requires medical guidance, NMN and senolytics are communicated with honest uncertainty.

The goal is not "live longer through more pills." The goal is: live the documented lifestyle levers consistently, and be honest about pharmacological bets — what is a bet and what is proven.

How we operationalize it

The platform for this world

Biological-age tracker

Log epigenetic age tests (Horvath, GrimAge), blood markers and lifestyle data — the AI calculates a trend curve instead of a single snapshot.

Studies database, human studies first

For every longevity substance you see human studies first — and when only mouse data exist, we say so loudly. No shifting promises across species boundaries.

Forum for longevity protocols

In the forum you exchange stacks, blood test trajectories and biomarkers — moderated by advisors with gerontology background, without MLM supplements.

Coach with a risk lens

In longevity the coach is especially strict: off-label rapamycin and metformin require medical guidance, NMN hype is contextualized, lifestyle levers come first.

Substances & topics

What is curated in Longevity

11 topics under continuous study monitoring. Each links to its full evidence overview.

FAQ

Frequently asked questions

Which longevity stack has the best evidence?
There is no pharmacological stack with proven life extension in humans. What we do have: lifestyle levers with hard outcome data — Mediterranean diet (PREDIMED, −30 % cardiovascular mortality), strength training (Momma 2022, −10–20 % all-cause), sleep 7–9 h (multiple cohorts), sauna 4–7×/week (Laukkanen, −50 % CV mortality). Pharmacologically, metformin and rapamycin are the most serious candidates — TAME trial on metformin is ongoing, data coming in years.
NMN — wonder molecule or hype?
Animal data impressive (mouse, monkey): NAD+ levels rise, mitochondrial function improves, some aging markers push back. Human RCTs: NAD+ rise measurable (250–500 mg/day, +30–60 % over 8 weeks), but no RCT with hard outcome endpoints in humans so far. Anyone taking it should treat it honestly as a bet — favorable side-effect profile, but no proven life extension. Spermidine, apigenin, pterostilbene have similarly strong animal, weak human evidence.
Rapamycin — the real game-changer?
Pharmacologically the most strongly validated substance for mammalian lifespan extension in animal trials. mTOR inhibition reproducibly extends mouse lifespan 9–14 %. Human data: approved for transplant patients, off-label in longevity practitioners in pulsatile dose (5–10 mg/week). Trade-offs: wound healing impairment, hyperlipidemia, insulin resistance, mucositis. Currently sensible only under medical guidance with clear monitoring.
Metformin for aging — what does TAME say?
Metformin has been a diabetes standard for decades with excellent safety profile. Observational data show diabetics on metformin sometimes have similar or better all-cause mortality than non-diabetics (Bannister study). The TAME trial (Targeting Aging with Metformin) is a US-NIH-funded Phase III RCT with 3000 participants testing whether metformin delays multimorbidity. Results expected from 2028. Off-label use in healthy adults: not yet sufficiently supported, but low risk.
Senolytics (fisetin, quercetin, dasatinib) — reality or speculation?
Animal data are strong: senolytics eliminate senescent cells and improve function across multiple tissues. Human RCTs: only very small Phase II studies in pulmonary fibrosis (Justice et al., n=14). Fisetin (in strawberries) is well-tolerated, high-dose protocols (20 mg/kg over 2–3 days, monthly) exist in forums — evidence for these is anecdotal, not RCT-based. Dasatinib is an oncology medication; off-label senolytic use without medical guidance is dangerous.
How to sensibly measure biological age?
Epigenetic clocks (Horvath, Hannum, GrimAge, PhenoAge, DunedinPACE) are currently the most reliable markers. DunedinPACE measures aging *rate*, not absolute age — more informative for tracking interventions. Cost: 200–500 € per test. Sensible: 1× baseline, then every 12–24 months with interventions. Important: daily fluctuations are large, sleep deprivation, illness or infection before the test give false signals. Overinterpreting individual values is a common mistake.
Caloric restriction in humans — really doable?
Classical CR (20–25 % caloric reduction with otherwise optimal nutrition) is tested in the CALERIE trial in humans — effects on metabolism, inflammation and aging markers positive, but the compliance problem is real and muscle mass / bone density losses significant. More practical: time-restricted eating (10–14 h window), seasonal fasting or modified CR with protein preservation. Longer fasts (3–5 days water or fasting-mimicking diet per Longo) 2–4× per year seems more cost-effective.
Lengthen telomeres — is that possible?
Telomeres shorten biologically with every cell division. TA-65 studies show modest telomerase-activating effects from an astragalus extract, but the correlation between longer telomeres and long life is weaker in humans than often portrayed — very long telomeres are even associated with increased cancer risk. More important practically than telomere lengthening: telomere protection through low inflammation, good mitochondrial function and avoidance of oxidative stress.
More worlds